Guardant Health Outcomes Model Confirms the Public Health Importance of Enhanced Colorectal Cancer Screening Outcomes with High Adherence Strategies
Guardant Health (Nasdaq: GH) announced the acceptance of its CAN-SCREEN model for publication in the Journal of Medical Economics. This health outcomes study emphasizes the importance of combining effective screening performance with high patient adherence in colorectal cancer (CRC) screening to optimize health outcomes. Unlike existing models, CAN-SCREEN accounts for both clinical efficacy and real-world adherence in predicting CRC incidence and mortality rates.
The study highlights the potential of Guardant Health's blood-based screening test, Shield™, to reduce CRC-related mortality due to its high adherence rates. The model predicts that integrating this non-invasive test into existing screening programs could significantly reduce CRC-related deaths, especially among previously unscreened populations. Patients screened with blood-based testing are predicted to gain more life years compared to those screened with FIT or mtsDNA tests.
Guardant Health (Nasdaq: GH) ha annunciato l'accettazione del suo modello CAN-SCREEN per la pubblicazione nel Journal of Medical Economics. Questo studio sui risultati sanitari sottolinea l'importanza di combinare performance di screening efficace con alta aderenza del paziente nello screening per il cancro colorettale (CRC) al fine di ottimizzare i risultati sanitari. A differenza dei modelli esistenti, CAN-SCREEN considera sia l'efficacia clinica che l'aderenza reale nella previsione dell'incidenza e dei tassi di mortalità per CRC.
Lo studio evidenzia il potenziale del test di screening basato sul sangue di Guardant Health, Shield™, di ridurre la mortalità legata al CRC grazie ai suoi alti tassi di aderenza. Il modello prevede che l'integrazione di questo test non invasivo nei programmi di screening esistenti potrebbe ridurre significativamente i decessi legati al CRC, specialmente tra le popolazioni precedentemente non sottoposte a screening. I pazienti sottoposti a screening con test basati sul sangue guadagnano più anni di vita rispetto a quelli sottoposti a test FIT o mtsDNA.
Guardant Health (Nasdaq: GH) anunció la aceptación de su modelo CAN-SCREEN para su publicación en el Journal of Medical Economics. Este estudio de resultados de salud enfatiza la importancia de combinar un rendimiento de detección efectivo con una alta adherencia del paciente en la detección del cáncer colorrectal (CRC) para optimizar los resultados de salud. A diferencia de los modelos existentes, CAN-SCREEN tiene en cuenta tanto la eficacia clínica como la adherencia en el mundo real al predecir las tasas de incidencia y mortalidad por CRC.
El estudio destaca el potencial del test de detección basado en sangre de Guardant Health, Shield™, para reducir la mortalidad relacionada con el CRC debido a sus altos índices de adherencia. El modelo predice que la integración de esta prueba no invasiva en los programas de detección ya existentes podría reducir significativamente las muertes relacionadas con el CRC, especialmente entre las poblaciones que no han sido sometidas a pruebas. Se predice que los pacientes sometidos a pruebas basadas en sangre ganarán más años de vida en comparación con aquellos sometidos a pruebas FIT o mtsDNA.
Guardant Health (Nasdaq: GH)는 CAN-SCREEN 모델의 등재가 Journal of Medical Economics에 발표되었다고 발표했습니다. 이 건강 결과 연구는 대장암(CRC) 스크리닝에서 효과적인 선별 성과와 높은 환자 순응도를 결합하는 것이 건강 결과를 최적화하는 데 중요하다는 점을 강조합니다. 기존 모델과 달리 CAN-SCREEN은 CRC 발병률과 사망률을 예측하는 데 있어 임상 효능과 실제 순응도를 모두 고려합니다.
이 연구는 Guardant Health의 혈액 기반 스크리닝 테스트인 Shield™가 높은 순응률로 인하여 CRC 관련 사망률을 줄일 수 있는 잠재력을 강조합니다. 이 모델은 기존의 스크리닝 프로그램에 비침습적인 이 검사를 통합하는 것이 CRC 관련 사망을 상당히 줄일 수 있다고 예측합니다. 혈액 기반 검사를 받은 환자는 FIT 또는 mtsDNA 검사를 받은 환자에 비해 더 많은 생명 연수를 얻을 것으로 예상됩니다.
Guardant Health (Nasdaq: GH) a annoncé l'acceptation de son modèle CAN-SCREEN pour publication dans le Journal of Medical Economics. Cette étude sur les résultats sanitaires souligne l'importance de combiner une performance de dépistage efficace avec une forte adhésion des patients dans le dépistage du cancer colorectal (CRC) afin d'optimiser les résultats sanitaires. Contrairement aux modèles existants, CAN-SCREEN prend en compte à la fois l'efficacité clinique et l'adhésion dans le monde réel pour prédire les taux d'incidence et de mortalité du CRC.
L'étude met en évidence le potentiel du test de dépistage sanguin de Guardant Health, Shield™, pour réduire la mortalité liée au CRC grâce à ses taux d'adhésion élevés. Le modèle prévoit que l'intégration de ce test non invasif dans les programmes de dépistage existants pourrait réduire considérablement les décès liés au CRC, en particulier parmi les populations non dépistées précédemment. Les patients dépistés par un test sanguin devraient gagner plus d'années de vie par rapport à ceux dépistés avec des tests FIT ou mtsDNA.
Guardant Health (Nasdaq: GH) gab die Annahme seines CAN-SCREEN Modells zur Veröffentlichung im Journal of Medical Economics bekannt. Diese Studie zu gesundheitlichen Ergebnissen betont die Bedeutung der Kombination aus effektiver Screening-Leistung und hoher Patientenadhärenz in der Früherkennung von kolorektalem Krebs (CRC), um die gesundheitlichen Ergebnisse zu optimieren. Im Gegensatz zu bestehenden Modellen berücksichtigt CAN-SCREEN sowohl klinische Wirksamkeit als auch die tatsächliche Adhärenz bei der Vorhersage von CRC-Inzidenz und Sterblichkeitsraten.
Die Studie hebt das Potenzial des blutbasierten Screening-Tests von Guardant Health, Shield™, hervor, die mit CRC verbundenen Mortalität aufgrund seiner hohen Adhärenzraten zu reduzieren. Das Modell prognostiziert, dass die Integration dieses nicht-invasiven Tests in bestehende Screening-Programme die CRC-verwandten Todesfälle erheblich senken könnte, insbesondere bei zuvor nicht gescreenten Bevölkerungsgruppen. Bei Patienten, die mit blutbasiertem Testing gescreent werden, wird vorhergesagt, dass sie mehr Lebensjahre gewinnen als diejenigen, die mit FIT- oder mtsDNA-Tests gescreent wurden.
- Acceptance of CAN-SCREEN model for publication in a medical journal
- Potential of Shield™ blood-based test to reduce CRC-related mortality
- Prediction of more life years gained with blood-based testing compared to FIT or mtsDNA
- None.
The acceptance of Guardant Health's CAN-SCREEN model for publication in the Journal of Medical Economics marks a significant advancement in colorectal cancer (CRC) screening strategies. This model's innovative approach, which considers both clinical efficacy and patient adherence, addresses a critical gap in existing screening models.
Key insights from the study include:
- The model predicts that blood-based screening tests like Shield™ could significantly reduce CRC-related mortality, particularly among previously unscreened populations.
- Patients screened with blood-based testing are projected to gain more life years compared to those screened with FIT or mtsDNA.
- The study highlights the importance of high adherence strategies in optimizing CRC-related health outcomes.
From a medical research perspective, this model could revolutionize how we approach CRC screening programs. By accounting for real-world patient behavior and preferences, it provides a more accurate prediction of population-level health outcomes. This could lead to more effective and targeted screening strategies, potentially saving countless lives through early detection and intervention.
However, it's important to note that while the model shows promise, real-world implementation and long-term studies will be important to validate these predictions. The medical community will be watching closely to see how this model translates into actual clinical practice and patient outcomes.
Guardant Health's announcement of the CAN-SCREEN model's acceptance for publication is a positive development for the company, potentially strengthening its position in the competitive precision oncology market. Here's why this matters from a financial perspective:
- Market Expansion: The model's focus on blood-based testing could drive increased adoption of Guardant's Shield™ test, potentially expanding its market share in the CRC screening space.
- Revenue Growth: If the model's predictions hold true, we could see increased demand for Guardant's blood-based tests, potentially leading to significant revenue growth.
- Competitive Advantage: The CAN-SCREEN model differentiates Guardant from competitors by emphasizing the importance of adherence in screening strategies, a factor often overlooked in traditional models.
- Long-term Value: By potentially reducing CRC-related deaths and increasing life years gained, Guardant's approach could create substantial long-term value for healthcare systems, strengthening its market position.
However, investors should be cautious. While the publication is promising, it doesn't guarantee immediate financial success. The company will need to effectively commercialize these findings and navigate regulatory hurdles to translate this research into tangible financial gains. Additionally, the competitive landscape in precision oncology remains intense, with other companies also developing innovative screening methods.
Overall, while this news is positive for Guardant Health, investors should monitor how effectively the company leverages this research to drive adoption of its blood-based tests and ultimately, its financial performance.
Research Study Accepted for Publication Demonstrates Efficacy of Blood-Based Tests for CRC Screening
The CAN-SCREEN model addresses the significant limitations of existing models, which often assume absolute adherence to screening protocols. These assumptions fail to accurately predict population-level health outcomes, overlooking the real-world challenges and preferences of patients. Guardant Health's innovative model accounts for both clinical efficacy and adherence in determining CRC incidence and mortality rates.
A key benefit of Guardant Health’s blood-based screening test, Shield™, is the potential to reduce CRC-related mortality due to its high adherence. This non-invasive screening modality is designed to maximize patient adherence, offering a more accessible and preferable option than traditional methods. By integrating this blood-based test into existing screening programs, the CAN-SCREEN model predicts a significant reduction in CRC-related deaths, particularly among previously unscreened populations. The model also predicts that patients screened with blood-based testing gained more life years, compared to those screened with FIT or mtsDNA.
“At Guardant Health, our mission is to enhance cancer detection and improve patient outcomes through innovative solutions,” said AmirAli Talasaz, Co-CEO of Guardant Health. “The CAN-SCREEN model's findings reinforce the critical role of adherence in CRC screening strategies. By leveraging our blood-based test, we are poised to substantially impact CRC screening adherence and ultimately save lives.”
Guardant Health remains committed to advancing precision oncology through groundbreaking research and state-of-the-art diagnostic tools. The CAN-SCREEN model represents a pivotal step forward in optimizing CRC screening strategies, ensuring that more patients benefit from early detection and timely intervention.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
References
Forbes, S. P., Yay Donderici, E., Zhang, N., et al. (2024). Population health outcomes of blood-based screening for colorectal cancer in comparison to current screening modalities: insights from a discrete-event simulation model incorporating longitudinal adherence. Journal of Medical Economics, 1–40. https://doi.org/10.1080/13696998.2024.2382036
View source version on businesswire.com: https://www.businesswire.com/news/home/20240801502329/en/
Investor Contact:
Zarak Khurshid
investors@guardanthealth.com
Media Contact:
Melissa Marasco
press@guardanthealth.com
Source: Guardant Health, Inc.
FAQ
What is the CAN-SCREEN model developed by Guardant Health (GH)?
How does Guardant Health's Shield™ test potentially impact colorectal cancer screening?
What are the predicted benefits of blood-based testing according to the CAN-SCREEN model?
